Загрузка...
Fibroblast growth factor 23: are we ready to use it in clinical practice?
Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity and mortality. Over the past decade it has come clear that a disturbed calcium-phosphate metabolism, with Fibroblast Growth Factor-23 as a key hormone, is partly accountable for this enhanced risk. Nu...
Сохранить в:
| Опубликовано в: : | J Nephrol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7220896/ https://ncbi.nlm.nih.gov/pubmed/32130720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40620-020-00715-2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|